Ditch Labs develops a drug-device combination inhaler and companion digital therapeutic for smoking and vaping cessation. The prescription-based DitchPen utilizes a dual aerosolization system to deliver nicotine replacement therapy with a gradual, personalized reduction schedule. This platform addresses both the physical nicotine dependence and the psychological triggers associated with tobacco use disorder.
Funding
$4.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ACFounders
Product
Problem
Smoking cessation is challenging due to nicotine addiction, which presents both physiological withdrawal symptoms and psychological dependencies. Current cessation methods often fail to address both aspects effectively, leading to relapse.
Solution
Ditch is developing the DitchPen®, a medical vaporizer that delivers controlled doses of nicotine, gradually reducing intake to aid in smoking cessation. Paired with a digital therapeutic application, the system addresses the physiological and psychological components of nicotine addiction. The DitchPen® aims to provide a seamless and precisely managed reduction in nicotine consumption, while the app offers support and strategies to manage cravings and change smoking-related behaviors. This integrated approach seeks to improve the success rates of individuals trying to quit smoking.
Target Audience
The primary target audience is individuals seeking to quit smoking who require a medically supported and digitally enhanced solution to manage both the physical and psychological challenges of nicotine addiction.
Features
- Patent-pending medical vaporizer for controlled nicotine delivery
- Gradual and seamless reduction of nicotine dosage
- Digital therapeutic application addressing psychological aspects of addiction
- Personalized support and strategies for managing cravings
- Integration of physiological and psychological treatment approaches